Luteinizing hormone releasing hormone human acetate salt (LHRH) |
| Katalog-Nr.GP10088 |
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 71447-49-9
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
Luteinizing hormone releasing hormone human acetate salt (LHRH) is a selective acitivator of MMP-2 and MMP-9 [1, 2].
Luteinizing hormone-releasing hormone (LHRH), also known as Gonadotropin-releasing hormone (GnRH) is a trophic peptide hormone which secreted by GnRH neurons and plays an important role in the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary [3].
MMP-2 (matrix metalloproteinase-2) and MMP-9 (matrix metalloproteinase-9) belong to the MMP family that play an important role in the breakdown of extracellular matrix (ECM) in normal physiological processes, for example, embryonic development, reproduction, and tissue remodeling, as well as in disease processes, such as arthritis and metastasis [2].
When tested with Ishikawa and ECC-1 cell lines, LHRH resulted in the increase of MMP-9 expression which induced cell invasion and it was also showed that GPR101 mediated the LHRH activity and cooperated to function in the metastatic potential of endometrial cancer cells [1]. In human decidual endometrial stromal cells, LHRH with its receptor induced the activation of MMP-2 and MMP-9 [2].
References:
[1].? Cho-Clark, M., et al., GnRH-(1-5) Activates Matrix Metallopeptidase-9 to release Epidermal Growth Factor and Promote Cellular Invasion. Mol Cell Endocrinol, 2015.
[2].? Wu, H.M., et al., Gonadotropin-releasing hormone type II (GnRH-II) agonist regulates the motility of human decidual endometrial stromal cells: possible effect on embryo implantation and pregnancy. Biol Reprod, 2015. 92(4): p. 98.
[3].? Garnick, M.B. and M. Campion, Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group. Mol Urol, 2000. 4(3): p. 275-7.
| Cas No. | 71447-49-9 | SDF | |
| Chemical Name | Luteinizing hormone releasing hormone human acetate salt | ||
| Canonical SMILES | CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)CNC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6 | ||
| Formula | C55H75N17O13 | M.Wt | 1182.29 |
| Löslichkeit | ≥118.2mg/mL in DMSO with ultrasonic; 25mg/ml in water | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 0.8458 mL | 4.2291 mL | 8.4582 mL |
| 5 mM | 0.1692 mL | 0.8458 mL | 1.6916 mL |
| 10 mM | 0.0846 mL | 0.4229 mL | 0.8458 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *